

Intranasal Gene Therapy for Dementia Demonstrates Cognitive Benefits

Five Participants Gain Cognitive Benefits After Receiving Intranasal Gene Therapy

SEATTLE, WA, UNITED STATES, November 11, 2021 /EINPresswire.com/ -- In a first-of-its-kind, sponsored safety study, five patients with mild to moderate dementia received a proprietary intranasal dual gene therapy composed of hTERT and Klotho. The study's findings were published this month in the peer-reviewed *Journal of Regenerative Biology and Medicine* in Volume 3; Issue 6 (2021).



Telomere shortening and the reduced expression of Klotho directly correlate with the diseases of aging, this study demonstrates the potential to successfully address aging at the cellular level"

CEO of BioViva USA Inc, Liz Parrish

The study was primarily structured for safety. The treatment demonstrated an excellent safety profile with no complications. Efficacy data was also collected and tracked, including immune system response, physical exams, telomere length, blood analyses, and brain imaging.

The beneficial effects of the treatment were demonstrated by a sustained improved score on the Folstein exam, a test

used to measure cognitive impairment. Improved Folstein scoring corresponds to improved memory and cognition. "This is a remarkable study considering that dementia patients' cognitive function declines predictably every year. Without therapy, a patient's score on the Folstein test declines approximately 3-points-per-year after diagnosis," stated Patrick Sewell, BioViva's Director of Clinical Affairs.

Systemic telomere lengthening was observed in all patients. Longer telomeres have been linked with a reduced risk for a myriad of age-related diseases and all-cause mortality. Telomere lengthening leads to longer replicative cell life and is associated with a younger biological age.

"Telomere shortening and the reduced expression of Klotho directly correlate with the diseases of aging," BioViva CEO Elizabeth Parrish stated, "this study demonstrates the potential to successfully address aging at the cellular level. Despite decades of effort and billions of dollars devoted to dementia research, we have seen very little progress...until now. Anyone who has lost a loved one to dementia understands the importance of this work."

The patent-pending study was carried out by Integrated Health Systems and was sponsored by

Maximum Life Foundation, a 501(c)(3) organization; [BioViva USA Inc.](#) evaluated the results.

About BioViva USA Inc.

BioViva USA Inc. is a company devoted to evaluating and developing gene therapies and new viral vectors to treat aging-associated diseases.

Contact: info@bioviva-science.com

About Integrated Health Systems Ltd.

IHS is an international consortium of medical specialists skilled at creating and delivering cutting-edge and tailored regenerative therapies.

Contact info@integrated-health-systems.com

Supporting Video: [Human Dementia Study: BioViva Analyzes the Data](#)

Elizabeth Parrish

BioViva USA Inc.

info@BioViva-Science.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/556056064>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.